228 related articles for article (PubMed ID: 16674097)
21. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.
Fleming JS; Beaugié CR; Haviv I; Chenevix-Trench G; Tan OL
Mol Cell Endocrinol; 2006 Mar; 247(1-2):4-21. PubMed ID: 16297528
[TBL] [Abstract][Full Text] [Related]
22. Common epithelial tumors of the ovary: proliferating and of low malignant potential.
Ulbright TM; Roth LM
Semin Diagn Pathol; 1985 Feb; 2(1):2-15. PubMed ID: 2832916
[TBL] [Abstract][Full Text] [Related]
23. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
Oe S; Hasegawa K; Nagase S; Kato R; Torii Y; Udagawa Y
Int J Gynecol Pathol; 2010 Sep; 29(5):405-10. PubMed ID: 20736762
[TBL] [Abstract][Full Text] [Related]
24. Ultrastructural study of benign, low-malignant potential (LMP), and malignant ovarian tumors.
Ishioka S; Sagae S; Ito E; Kudo R
Med Electron Microsc; 2004 Mar; 37(1):37-44. PubMed ID: 15057603
[TBL] [Abstract][Full Text] [Related]
25. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
26. Classifications of ovarian cancer tissues by proteomic patterns.
Zhu Y; Wu R; Sangha N; Yoo C; Cho KR; Shedden KA; Katabuchi H; Lubman DM
Proteomics; 2006 Nov; 6(21):5846-56. PubMed ID: 17068758
[TBL] [Abstract][Full Text] [Related]
27. Proteomic analysis reflects different histologic subtypes of epithelial ovarian cancer.
Jia L; Zhang H; Qu X; Deng B; Kong B
Med Hypotheses; 2012 Mar; 78(3):407-9. PubMed ID: 22227042
[TBL] [Abstract][Full Text] [Related]
28. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
[TBL] [Abstract][Full Text] [Related]
29. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
30. Molecular proteomics imaging of tumor interfaces by mass spectrometry.
Kang S; Shim HS; Lee JS; Kim DS; Kim HY; Hong SH; Kim PS; Yoon JH; Cho NH
J Proteome Res; 2010 Feb; 9(2):1157-64. PubMed ID: 19821573
[TBL] [Abstract][Full Text] [Related]
31. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
33. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
35. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
[TBL] [Abstract][Full Text] [Related]
36. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
Drapkin R; von Horsten HH; Lin Y; Mok SC; Crum CP; Welch WR; Hecht JL
Cancer Res; 2005 Mar; 65(6):2162-9. PubMed ID: 15781627
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
39. Mucinous tumors of the ovary: a review.
Hart WR
Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
[TBL] [Abstract][Full Text] [Related]
40. Origins and molecular pathology of ovarian cancer.
Bell DA
Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]